Answers are grounded in this paper and cite their sources.
Compares three-year survival outcomes in ALD and MASH liver transplant recipients, indicating the need for better management strategies.
OBJECTIVES: We compared temporal trends in three-year survival trends for patients who underwent liver transplantation (LT) for ALD and MASH. METHODS: Utilizing the UNOS registry, we examined three-year post-LT survival, stratified by etiology and year of LT, using Kaplan-Meier analysis with log-rank testing. RESULTS: Three-year survival was similar for ALD and MASH pre-COVID (88.7% vs. 88.5%, p=0.860) but diverged during COVID, with ALD showing higher survival (90.3% vs. 86.9%, p<0.001), particularly among White and Hispanic recipients. CONCLUSIONS: ALD recipients show excellent and improving survival, while MASH recipients' declining survival highlights the need for better risk stratification and management.
No takes yet. Share an insight, caveat, or question.
Machicao et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: